Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

SUMMARY: BACKGROUND AND OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This is a pros...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Higashihara, Eiji, Torres, Vicente E., Chapman, Arlene B., Grantham, Jared J., Bae, Kyongtae, Watnick, Terry J., Horie, Shigeo, Nutahara, Kikuo, Ouyang, John, Krasa, Holly B., Czerwiec, Frank S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Nephrology 2011
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3359559/
https://ncbi.nlm.nih.gov/pubmed/21903984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.03530411
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi